Pharmacological and physical prevention and treatment of no-reflow after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction

Journal of International Medical Research

Volumn 41, Issue 3, 2013, Pages 537-547

  Guo, Ao Qiang ^a   Sheng, Lei ^b   Lei, Xu ^b   Shu, Wang ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

No reflow; prevention; primary percutaneous coronary intervention; ST segment elevation myocardial infarction; treatment

Indexed keywords

4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; ATRIAL NATRIURETIC FACTOR; CARVEDILOL; CHINESE DRUG; CLOPIDOGREL; CYCLOSPORIN A; EPTIFIBATIDE; FIBRIN DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; FOSINOPRIL; FX 06; MORPHINE; NICORANDIL; NITRATE; NITROPRUSSIDE SODIUM; PLACEBO; RETEPLASE; STATIN (PROTEIN); TONGXINLUO; UNCLASSIFIED DRUG; VALSARTAN; VERAPAMIL;

ARTICLE; BALLOON DILATATION; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; EMBOLIC PROTECTION DEVICE; EMBOLISM; GLYCEMIC CONTROL; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; INTRACORONARY DRUG ADMINISTRATION; NO REFLOW PHENOMENON; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBUS ASPIRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

NO-REFLOW; PREVENTION; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; EMBOLISM, AIR; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; VASODILATOR AGENTS;

EID: 84887370619     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513479859     Document Type: Article

References (73)

1. Keeley EC,Boura JA,Grines CL.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.Lancet. 2003;361:13-20.
2. Niccoli G,Burzotta F,Galiuto L,et al.Myocardial no-reflow in humans.J Am Coll Cardiol. 2009;54:281-292.
3. Rezkalla SH,Kloner RA.Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory.Catheter Cardiovasc Interv. 2008;72:950-957.
4. Reffelmann T,Kloner RA.The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion.Basic Res Cardiol. 2006;101:359-372.
5. Zhao JL,Yang YJ,You SJ,et al.Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion.Coron Artery Dis. 2006;17:463-469.
6. Guan S,Wang B.Effects of fosinopril and valsartan on expressions of ICAM-1 and NO in human umbilical vein endothelial cells.Chin Med J (Engl). 2003;116:923-927.
7. Zhao J,Yang Y,You S,et al.Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion.Int J Cardiol. 2007;115:334-341.
8. Peart JN,Headrick JP.Clinical cardioprotection and the value of conditioning responses.Am J Physiol Heart Circ Physiol. 2009;296:H1705-1720.
9. Hill M,Takano H,Tang XL,et al.Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance.Circulation. 2001;104:694-699.
10. Parker JO.Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina.J Am Coll Cardiol. 1989;13:794-795.
11. Ambrosio G,Del Pinto M,Tritto I,et al.for the GRACE Investigators. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events.Eur Heart J. 2010;31:430-438.
12. Blackburn MR,Vance CO,Morschl E,et al.Adenosine receptors and inflammation.Handb Exp Pharmacol. 2009;193:215-269.
13. Bullough DA,Magill MJ,Firestein GS,et al.Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes.J Immunol. 1995;155:2579-2586.
14. Sommerschild HT,Kirkebøen KA.Adenosine and cardioprotection during ischaemia and reperfusion - an overview.Acta Anaesthesiol Scand. 2000;44:1055-1038.
15. Marzilli M,Orsini E,Marraccini P,et al.Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.Circulation. 2000;101:2154-2159.
16. Claeys MJ,Bosmans J,De Ceuninck M,et al.Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction.Am J Cardiol. 2004;94:9-13.
17. Grygier M,Araszkiewicz A,Lesiak M,et al.New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention.Am J Cardiol. 2011;107:1131-1135.
18. Fokkema ML,Vlaar PJ,Vogelzang M,et al.Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.Circ Cardiovasc Interv. 2009;2:323-329.
19. Stoel MG,Marques KM,de Cock CC,et al.High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study.Catheter Cardiovasc Interv. 2008;7:283-289.
20. Mahaffey KW,Puma JA,Barbagelata NA,et al.Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.J Am Coll Cardiol. 1999;34:1711-1720.
21. Ross AM,Gibbons RJ,Stone GW,et al.for the AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).J Am Coll Cardiol. 2005;45:1775-1780.
22. Kloner RA,Forman MB,Gibbons RJ,et al.Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.Eur Heart J. 2006;27:2400-2405.
23. Kopecky SL,Aviles RJ,Bell MR,et al.A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study.Am Heart J. 2003;146:146-152.
24. Falase B,Easaw J,Youhana A.The role of nicorandil in the treatment of myocardial ischaemia.Expert Opin Pharmacother. 2001;2:845-856.
25. Tanaka H,Okazaki K,Shigenobu K.Cardioprotective effects of NIP-121, a novel ATP-sensitive potassium channel opener, during ischemia and reperfusion in coronary perfused guinea pig myocardium.J Cardiovasc Pharmacol. 1996;27:695-701.
26. Ishii H,Ichimiya S,Kanashiro M,et al.Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction.Circulation. 2005;112:1284-1288.
27. Ito H,Taniyama Y,Iwakura K,et al.Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction.J Am Coll Cardiol. 1999;33:654-660.
28. Ono H,Osanai T,Ishizaka H,et al.Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation.Am Heart J. 2004;148:E15-E15.
29. Kitakaze M,Asakura M,Kim J,et al.for the J-WIND Investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.Lancet. 2007;370:1483-1493.
30. Taniyama Y,Ito H,Iwakura K,et al.Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction.J Am Coll Cardiol. 1997;30:1193-1199.
31. Werner GS,Lang K,Kuehnert H,et al.Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction.Catheter Cardiovasc Interv. 2002;57:444-451.
32. Zhang LM,Castresana M,Newman WH.Variability of response to atrial natriuretic peptide and sodium nitroprusside in cultured vascular smooth muscle cells from three blood vessels.Crit Care Med. 1994;22:1461-1464.
33. Pasceri V,Pristipino C,Pelliccia F,et al.Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction.Am J Cardiol. 2005;95:1358-1361.
34. Airoldi F,Briguori C,Cianflone D,et al.Frequency of slow coronary flow following successful stent implantation and effect of nitroprusside.Am J Cardiol. 2007;99:916-920.
35. Amit G,Cafri C,Yaroslavtsev S,et al.Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.Am Heart J. 2006;152:e9-14.
36. Javadov SA,Clarke S,Das M,et al.Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart.J Physiol. 2003;549:513-524.
37. Piot C,Croisille P,Staat P,et al.Effect of cyclosporine on reperfusion injury in acute myocardial infarction.N Engl J Med. 2008;359:473-481.
38. Atar D,Petzelbauer P,Schwitter J,et al.for the F.I.R.E. Investigators. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.J Am Coll Cardiol. 2009;53:720-729.
39. Zhang HT,Jia ZH,Zhang J,et al.No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial).Chin Med J (Engl). 2010;123:2858-2864.
40. Shimizu M,Saxena P,Konstantinov IE,et al.Remote ischemic preconditioning decreases adhesion and selectively modifies functional responses of human neutrophils.J Surg Res. 2010;158:155-161.
41. Kharbanda RK,Nielsen TT,Redington AN.Translation of remote ischaemic preconditioning into clinical practice.Lancet. 2009;374:1557-1565.
42. Posa A,Pavo N,Hemetsberger R,et al.Protective effect of ischaemic preconditioning on ischaemia/reperfusion-induced microvascular obstruction determined by on-line measurements of coronary pressure and blood flow in pigs.Thromb Haemost. 2010;103:450-460.
43. Bøtker HE,Kharbanda R,Schmidt MR,et al.Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.Lancet. 2010;375:727-734.
44. Hansen PR,Thibault H,Abdulla J.Postconditioning during primary percutaneous coronary intervention: a review and meta-analysis.Int J Cardiol. 2010;144:22-25.
45. Rentoukas I,Giannopoulos G,Kaoukis A,et al.Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action.JACC Cardiovasc Interv. 2010;3:49-55.
46. Garcia S,Henry TD,Wang YL,et al.Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction.J Cardiovasc Transl Res. 2011;4:92-98.
47. Napodano M,Ramondo A,Tarantini G,et al.Predictors and time-related impact of distal embolization during primary angioplasty.Eur Heart J. 2009;30:305-313.
48. Niccoli G,Spaziani C,Marino M,et al.Effect of chronic aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction.Am J Cardiol. 2010;105:587-591.
49. Gibson CM,de Lemos JA,Murphy SA,et al.Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.Circulation. 2001;103:2550-2554.
50. Romagnoli E,Burzotta F,Trani C,et al.Rationale for intracoronary administration of abciximab.J Thromb Thrombolysis. 2007;23:57-63.
51. Petronio AS,De Carlo M,Ciabatti N,et al.Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine.Am Heart J. 2005;150:1015-1015.
52. Montalescot G,Antoniucci D,Kastrati A,et al.Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.Eur Heart J. 2007;28:443-449.
53. Thiele H,Schindler K,Friedenberger J,et al.Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.Circulation. 2008;118:49-57.
54. Gu YL,Kampinga MA,Wieringa WG,et al.Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.Circulation. 2010;122:2709-2717.
55. Prati F,Petronio S,Van Boven AJ,et al.for the FINESSE-ANGIO Substudy Investigators. Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events-Angiographic) study.JACC Cardiovasc Interv. 2010;3:1284-1291.
56. Schulz S,Birkmeier KA,Ndrepepa G,et al.One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial.Clin Res Cardiol. 2010;99:795-802.
57. Deibele AJ,Jennings LK,Tcheng JE,et al.Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the IntraCoronary Eptifibatide (ICE) trial.Circulation. 2010;121:784-791.
58. Svilaas T,Vlaar PJ,van der Horst IC,et al.Thrombus aspiration during primary percutaneous coronary intervention.N Engl J Med. 2008;358:557-567.
59. Kunadian B,Dunning J,Vijayalakshmi K.Meta-analysis of randomized trials comparing anti-embolic devices with standard PCI for improving myocardial reperfusion in patients with acute myocardial infarction.Catheter Cardiovasc Interv. 2007;69:488-496.
60. De Luca G,Suryapranata H,Stone GW,et al.Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials.Am Heart J. 2007;153:343-353.
61. Burzotta F,Testa L,Giannico F,et al.Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials.Int J Cardiol. 2008;123:313-321.
62. Silva-Orrego P,Colombo P,Bigi R,et al.Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study.J Am Coll Cardiol. 2006;48:1552-1559.
63. Ali A,Cox D,Dib N,et al.Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study.J Am Coll Cardiol. 2006;48:244-252.
64. Kaltoft A,Bøttcher M,Nielsen SS,et al.Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial.Circulation. 2006;114:40-47.
65. Stone GW,Webb J,Cox DA,et al.for the Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial.JAMA. 2005;293:1063-1072.
66. Gick M,Jander N,Bestehorn HP,et al.Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation.Circulation. 2005;112:1462-1469.
67. Vignali L,Talanas G,Saia F,et al.Genetic association between the 1976T_C polymorphism in the adenosine A2 receptor and angiographic no-reflow phenomenon.Il giornale italiano di Cardiologia Invasiva. 2007;3:109-109.
68. Collet JP,Montalescot G.The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes.Diab Vasc Dis Res. 2005;2:136-143.
69. Golino P,Maroko PR,Carew TE.The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion.Circulation. 1987;75:292-298.
70. Lexis CP,van der Horst IC,Rahel BM,et al.Impact of chronic total occlusions on markers of reperfusion, infarct size, and long-term mortality: a substudy from the TAPAS-trial.Catheter Cardiovasc Interv. 2011;77:484-491.
71. Ohshima K,Ikeda S,Watanabe K,et al.Relationship between plaque composition and no-reflow phenomenon following primary angioplasty in patients with ST-segment elevation myocardial infarction - analysis with virtual histology intravascular ultrasound.J Cardiol. 2009;54:205-213.
72. Iwakura K,Ito H,Kawano S,et al.Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction.Eur Heart J. 2006;27:534-539.
73. Malmberg K,Rydén L,Efendic S,et al.Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.J Am Coll Cardiol. 1995;26:56-65.